Medtronic's LigaSure RAS Maryland Device Cleared by FDA, Boosting Robotic Surgery Capabilities

Medtronic has just received a critical green light from the U.S. Food and Drug Administration (FDA) for its LigaSure RAS Maryland jaw device, specifically for use with the company's Hugo robotic-assisted surgery (RAS) system. This clearance marks a significant expansion of the Hugo system's capabilities, bringing Medtronic well-established LigaSure vessel sealing technology into the realm of robotic-assisted procedures in the United States. The move is a calculated escalation in the intense battle for dominance in the rapidly growing robotic surgery market, where Medtronic aims to challenge the long-held leadership of Intuitive Surgical and its da Vinci system. The LigaSure RAS Maryland device, which received its CE Mark in Europe in 2025, allows surgeons performing robotic operations to dissect, seal, and cut vessels and thick tissues up to 7mm with exceptional precision and efficiency, reportedly sealing vessels in just two seconds and minimizing thermal spread. This follows the Hugo RAS system initial FDA clearance in December 2025 for urologic surgical procedures, with its commercial launch in the U.S. in February 2026, and signals Medtronic intent to broaden the platform's applications into high-volume specialties like general and gynecologic surgery. Looking ahead, Medtronic has already submitted further 510(k) filings to expand the Hugo system's indications for general and gynecologic surgical procedures, promising a wider array of robotic-assisted options for more patients. As robotic-assisted surgery continues its rapid adoption globally, driven by demand for minimally invasive techniques and improved patient outcomes, this latest clearance positions Medtronic to significantly enhance its competitive footprint. Watch for further developments as Medtronic pushes to integrate more advanced instruments, aiming to make robotic surgery a more routine and accessible option for complex procedures.